Brian E. Lewis MD, MPH, FACP
Assistant Professor of Clinical Medicine, Department of Hematology and Medical Oncology, Tulane University School of Medicine, New Orleans, LouisianaBiographical Sketch:
Dr. Brian Lewis is an Assistant Professor of Clinical Medicine in the Department of Hematology and Medical Oncology at Tulane University School of Medicine in New Orleans. He is also the Chair of the Fellowship Advancement Committee of the Hematology and Medical Oncology Fellowship Program at Tulane.
Following his graduation from George Mason University in Fairfax, Virginia, Dr. Lewis enrolled in the Tulane University School of Public Health and, upon completing his MPH degree, entered medical school at Tulane. He completed his medical degree and residency training in internal medicine at Tulane, where he also completed his fellowship in hematology and medical oncology.
Dr. Lewis is a member of several professional societies, including the American Society of Hematology and the American Society of Clinical Oncology. Dr. Lewis is a Fellow of the American College of Physicians.
Positions:
Assistant Professor of Clinical Medicine, Department of Hematology and Medical Oncology; Chair, Fellowship Advancement Committee, Hematology and Medical Oncology Fellowship Program, Tulane University School of Medicine
Degrees:
MPH: Tulane University School of Public Health, New Orleans, Louisiana
MD: Tulane University School of Medicine
Disclosures
Dr. Brian Lewis does not have any financial interests to disclose.
Recent Contributions to PracticeUpdate:
- 2015 Top Stories in Advanced Prostate Cancer: ECOG CHAARTED Trial
- Optimal Sequence of Treatment Options in Metastatic Prostate Cancer
- Effect of BRCA Mutations on Metastatic Relapse and Cause-Specific Survival After Radical Treatment for Localized Prostate Cancer
- The Heterogeneity of High-Risk Prostate Cancer
- Smokers at Increased Risk for Biochemical Recurrence Post Prostatectomy
- Perioperative Outcomes After Radical Prostatectomy for Distant Metastatic Prostate Cancer at Presentation
- Urinary Complications From Metastatic Prostate Cancer
- Order of Cabazitaxel and Abiraterone Does Not Affect Survival in mCRPC Treated Previously With Docetaxel